American Journal of Clinical Dermatology

, Volume 8, Issue 1, pp 1–11 | Cite as

Acquired Palmoplantar Keratoderma

  • Shaily Patel
  • Matthew Zirwas
  • Joseph C. EnglishIII
Review Article

Abstract

Palmoplantar keratodermas (PPKs) are a diverse entity of disorders that are characterized by abnormal thickening of the skin on the palms and soles. Traditionally they have been classified as either hereditary or acquired and are distinguished from each other on the basis of mode of inheritance, presence of transgrediens (defined as contiguous extension of hyperkeratosis beyond the palmar and/or plantar skin), co-morbidities with other symptoms, and extent of epidermal involvement, namely diffuse, focal, and punctate. As the terms hyperkeratosis and keratoderma have been used interchangeably throughout the literature, we define acquired keratoderma as a non-hereditary, non-frictional hyperkeratosis of the palms and/or soles that involves ≥50% of the surface of involved acral areas and that may or may not be associated with clinical and histologic inflammation.

Given the numerous possible underlying causes for acquired PPKs, evaluation of patients presenting with acquired PPK can be a perplexing task. To facilitate such evaluations, this review categorizes the acquired PPKs as: keratoderma climactericum, drug related, malnutrition associated, chemically induced, systemic disease related, malignancy associated, dermatoses related, infectious, and idiopathic. In order to avoid the possibility of overlooking an underlying etiology and to eliminate excessive testing, we present an algorithm for assessing patients presenting with acquired PPK. The first step should include a comprehensive history and a physical examination, including a complete skin examination. If findings are consistent with a hereditary keratoderma, then a genetics consultation should be considered. Any findings suggestive of underlying conditions should be aggressively evaluated and treated. If no pertinent findings are identified after a history and a physical examination, laboratory and radiology studies should be undertaken in a systematic, logical fashion.

In terms of treatment, the most successful results occur when the underlying etiology is diagnosed and treated. If no such etiology is evident, then conservative treatment options include topical keratolytics (urea, salicylic acid, lactic acid), repeated physical debridement, topical retinoids, topical psoralen plus UVA, and topical corticosteroids. Etretinate and acitretin have also shown some success as alternative treatments in recalcitrant cases.

References

  1. 1.
    Arnold Jr HL; Odom RB; James WD.: Andrews’ diseases of the skin: clinical dermatology. 8th ed. Philadelphia (PA)WB Saunders, 1990Google Scholar
  2. 2.
    Freedberg M, Eisen AK, Wolff K.: Fitzpatrick’s dermatology in general medicine. 6th ed. New York McGraw-Hill,2003Google Scholar
  3. 3.
    Champion RH, Burton JL, Burns DA.: Rook, Wilkinson, Ebling textbook of dermatology. 7th ed. Malden (MA): Blackwell Science Ltd, 2004: 34, 79–107Google Scholar
  4. 4.
    Bolognia JL, Jorizzo JL, Rapini RP.: Dermatology. New York: Mosby, 2003: 809–10Google Scholar
  5. 5.
    Stevens HP, Kelsell DP, Bryant SP.: Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24: literature survey and proposed updated classification of the keratodermas. Arch Dermatol 1996; 132: 640–51Google Scholar
  6. 6.
    Itin PH, Fistrol SK.: Palmoplantar keratodermas. Clin Dermatol 2005; 23: 15–22PubMedCrossRefGoogle Scholar
  7. 7.
    Farmer ER, Hood AF.: Pathology of the skin. 2nd ed. New York: McGraw-Hill, 1990: 143, 653–4Google Scholar
  8. 8.
    Weedon D.: Skin pathology. 2nd ed. New York Churchill Livingstone, 2002Google Scholar
  9. 9.
    McKee PH.: Pathology of the skin. 2nd ed. Chicago (IL) Mosby-Wolfe, 1996Google Scholar
  10. 10.
    McCarthy L.: Histopathology of skin diseases. St. Louis (MO) CV Mosby Company, 1931: 36–7, 96-8 and 118-9Google Scholar
  11. 11.
    Elder D, Elenitsas R, Jaworsky.: Lever’s histopathology of the skin. 8th ed. Philadelphia (PA) Lippincott-Raven,1997Google Scholar
  12. 12.
    Barnhill RL, Busam KJ, Crowson AN. Textbook of dermatopathology. New York McGraw Hill, 1998: 287–8, 499 Fig. 8. Idiopathic acquired palmoplantar keratoderma in a patient with no family history of keratoderma and no evidence of malignancy to date.Google Scholar
  13. 13.
    Haxthausen H.: Keratoderma climactericum. Br J Dermatol 1934; 46: 161–7CrossRefGoogle Scholar
  14. 14.
    Deschamps P, Leroy D, Pedailles S.: Keratoderma climactericum (Haxthausen’s disease): clinical signs, laboratory findings and etretinate treatment in 10 patients. Dermatologica 1986; 172: 258–62Google Scholar
  15. 15.
    Lynch FW.: Keratoderma climactericum (Haxthausen). Arch Derm 1943; 48: 270–81CrossRefGoogle Scholar
  16. 16.
    Wathcel TJ.: Plantar and palmar hyperkeratosis in young castrated women. Int J Dermatol 1981; 20: 270–1CrossRefGoogle Scholar
  17. 17.
    Brincat M, Moniz CJ, Studd JW.: Long term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985; 92: 256–9PubMedCrossRefGoogle Scholar
  18. 18.
    Shuster S, Black MM, McVitie E.: The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol 1975; 93: 639–43PubMedCrossRefGoogle Scholar
  19. 19.
    Zultak M, Bedeaux C, Blanc D.: Keratoderma climactericum treatment with topical estrogen. Dermatologica 1988; 176: 151–2PubMedCrossRefGoogle Scholar
  20. 20.
    Sass U, Grosshans E, Simonart JM.: Chronic arsenicism: criminal poisoning or drug-intoxication? Dermatology 1993; 186: 303–5PubMedCrossRefGoogle Scholar
  21. 21.
    Poskitt LB, Duffill MB, Rademaker MR. Chloracne, palmoplantar keratoderma and localized scleroderma in a weed sprayer. Clin Exp Dermatol 1994; 19: 264–7PubMedCrossRefGoogle Scholar
  22. 22.
    Shannon RS, Strayer DS.: Arsenic induced skin toxicity. Hum Toxicol 1989; 8: 99–104PubMedCrossRefGoogle Scholar
  23. 23.
    Rahman MM, Chowdhury UK, Mukherjee SC.: Chronic arsenic toxicity in Bangladesh and West Bengal, India: a review and commentary. J Toxicol Clin Toxicol 2001; 39 (7): 683–700Google Scholar
  24. 24.
    Tindall JP.: Chloracne and chloracnegens. J Am Acad Dermatol 1985; 13: 539–58PubMedCrossRefGoogle Scholar
  25. 25.
    Geusau A, Jurecka W, Nahavandi H.: Punctate keratoderma-like lesions on the palms and soles in a patient with chloracne: a new clinical manifestation of dioxin intoxication? Br J Dermatol 2000; 143 (5): 1067–71Google Scholar
  26. 26.
    Lee BY, Hogan DJ, Ursine S.: Personal observation of skin disorders in malnutrition. Clin Dermatol 2006; 24: 222–7PubMedCrossRefGoogle Scholar
  27. 27.
    Duvic M, Reisman M, Finley V.: Glucan-induced keratoderma in acquired immunodeficiency syndrome. Arch Dermatol 1987; 123: 751–6PubMedCrossRefGoogle Scholar
  28. 28.
    Albersheim P, Darvill AG. Oligosaccharins. Sci Am 1985; 253: 58–64CrossRefGoogle Scholar
  29. 29.
    Jucgla A, Sais G, Navarro M.: Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131 (sn3): 364–5PubMedCrossRefGoogle Scholar
  30. 30.
    Lambert D, Beer F, Gisselman R.: Cutaneous lesions due to lithium therapy. Ann Dermatol Venereol 1982; 109 (1): 19–24PubMedGoogle Scholar
  31. 31.
    Reiffers J, Dick P.: Cutaneous side effects of treatment with lithium. Dermatologica 1977; 155 (sn3): 155–63PubMedCrossRefGoogle Scholar
  32. 32.
    Dalle S, Becuwe C, Balme B.: Venlafaxine-associated psoriasiform palmoplantar keratoderma and subungual hyperkeratosis. Br J Dermatol 2006; 154: 999–1000PubMedCrossRefGoogle Scholar
  33. 33.
    Tsuji T, Sawabe M.: Hyperpigmentation in striae distensae after bleomycin treatment. J Am Acad Dermatol 1993; 3: 503–5CrossRefGoogle Scholar
  34. 34.
    Blum RH, Carter SK, Agre K. A clinical review of bleomycin: a new antineoplastic agent. Cancer 1973; 31: 903–13PubMedCrossRefGoogle Scholar
  35. 35.
    Branski EE, Ware RE, Prose NS.: Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J Am Acad Dermatol 2001; 44: 859–61CrossRefGoogle Scholar
  36. 36.
    Kennedy BJ, Smith LR, Goltz RW.: Skin changes secondary to hydroxyurea therapy. Arch Dermatol 1975; 111: 183–7PubMedCrossRefGoogle Scholar
  37. 37.
    Chaine B, Neonato MG, Girot R.: Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 2001; 137: 467–70PubMedGoogle Scholar
  38. 38.
    Burns DA, Sarkany I, Gaylarde P.: Effects of hydroxyurea therapy on normal skin: a case report. Clin Exp Dermatol 1980; 5: 447–9PubMedCrossRefGoogle Scholar
  39. 39.
    Major P.: Verapamil as a cause of palmar hyperkeratosis. Tidsskr Nor Laegeforen 1983; 103: 2061PubMedGoogle Scholar
  40. 40.
    Bauer F.: Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). J Am Acad Dermatol 1981; 4: 239–48PubMedCrossRefGoogle Scholar
  41. 41.
    Bauer F.: Sequelae of Atabrine? dermatitis in Australian ex-servicemen. Aust J Dermatol 1962; 6: 311–9PubMedCrossRefGoogle Scholar
  42. 42.
    Miller JJ, Roling D, Spiers E.: Palmoplantar keratoderma associated with hypothyroidism. Br J Dermatol 1998; 139: 741–2PubMedCrossRefGoogle Scholar
  43. 43.
    Shaw WM, Mason EH, Kaltz EG.: Hypothyroidism, liver damage and vitamin A deficiency as factors in hyperkeratosis. Arch Dermatol Syph 1952; 66: 197–203CrossRefGoogle Scholar
  44. 44.
    Good JM, Neill SM, Rowland Payne CME.: Keratoderma of myxoedema. Clin Exp Dermatol 1988; 13: 339–41PubMedCrossRefGoogle Scholar
  45. 45.
    Hodak E, David M, Feuerman EJ.: Palmoplantar keratoderma in association with myxedema. Acta Derm Venerol 1986; 66: 354–7PubMedGoogle Scholar
  46. 46.
    Tan OT, Sarkany I.: Sever palmar keratoderma in myxoedema. Clin Exp Dermatol 1977; 2: 287–8PubMedCrossRefGoogle Scholar
  47. 47.
    Zouboulis CC, Biczo S, Gollnick H.: Elephantiasis nostras verrucosa: beneficial effect of oral etretinate therapy. Br J Dermatol 1992; 127: 411–6PubMedCrossRefGoogle Scholar
  48. 48.
    Parnell DD, Johnson SA.: Tylosis palmaris et plantaris: its occurrence with internal malignancy. Arch Dermatol 1969; 100: 7–9PubMedCrossRefGoogle Scholar
  49. 49.
    Millard LG, Gould DJ.: Hyperkeratosis of the palms and soles associated with internal malignancy and elevated levels of immunoreactive human growth hormone. Clin Exp Dermatol 1976; 1: 363–8PubMedCrossRefGoogle Scholar
  50. 50.
    Powell F, Mackey JP.: Bronchial carcinoma and hyperkeratosis palmaris et plantaris. Postgrad Med J 1981; 57: 57–9PubMedCrossRefGoogle Scholar
  51. 51.
    Cuzick J, Harris R, Mortimer PS.: Palmar keratoses and cancers of the bladder and lung. Lancet 1984; I: 530–3CrossRefGoogle Scholar
  52. 52.
    Murata Y, Kumano K, Tani M.: Acquired diffuse keratoderma of the palms and soles with bronchial carcinoma: report of a case and review of the literature. Arch Dermatol 1988; 124: 497–8PubMedCrossRefGoogle Scholar
  53. 53.
    Kerdel FA, MacDonald DM.: Palmo-plantar keratoderma associated with carcinoma of the bronchus. Acta Dermato Venereol 1982; 62 (2): 178–80Google Scholar
  54. 54.
    Khanna SK, Agnone FA, Leibowitz AI.: Nonfamilial diffuse palmoplantar keratoderma associated with bronchial carcinoma. J Am Acad Dermatol 1993; 28: 295–7PubMedCrossRefGoogle Scholar
  55. 55.
    Murata I, Ogami Y, Nagai Y.: Carcinoma of the stomach with hyperkeratosis palmaris et plantaris and acanthosis of the esophagus. Am J Gastroenterol 1998; 93 (3): 449–51PubMedCrossRefGoogle Scholar
  56. 56.
    Abadir R, Zurowski S. Case report: squamous cell carcinoma of the skin in both acrokerpalms, axillary node, donor skin graft site and both soles: associated hyperkeratosis and porokeratosis. Br J Radiol 1994; 67: 507–10PubMedCrossRefGoogle Scholar
  57. 57.
    Smith CH, Barker JN, Hay RJ.: Diffuse plane xanthomatosis and acquired palmoplantar keratoderma in association with myeloma. Br J Dermatol 1995; 132: 286–9PubMedCrossRefGoogle Scholar
  58. 58.
    Tomsick RS.: Hyperkeratosis in mycosis fungoides. Cutis 1982; 29: 621–3PubMedGoogle Scholar
  59. 59.
    Taswell HF, Winkelmann RK.: Śezary syndrome: a malignant reticulemic erythroderma. JAMA 1961; 177: 465–72PubMedCrossRefGoogle Scholar
  60. 60.
    Fleischmajer R, Eisenberg S.: Śezary’s reticulosis: its relationship with neoplasias of the lymphoreticular system. Arch Dermatol 1964; 89: 9–19PubMedCrossRefGoogle Scholar
  61. 61.
    Howel Evans W, McConnell RB, Clarke CA.: Carcinoma of the oesophagus with keratosis palmaris et plantaris (tylosis). Q J Med 1958; 27: 413–29Google Scholar
  62. 62.
    Bazex A, Griffiths A.: Acrokeratosis paraneoplastica: a new cutaneous marker of malignancy. Br J Dermatol 1980; 102: 301–6CrossRefGoogle Scholar
  63. 63.
    Pecora AL, Landsman L, Imgrund SP.: Acrokeratosis paraneoplastica (Bazex’ syndrome). Arch Dermatol 1983; 119: 820–6PubMedCrossRefGoogle Scholar
  64. 64.
    Jacobsen FK, Abildtrup N, Laursen SO.: Acrokeratosis paraneoplastica (Bazex’ syndrome). Ach Dermatol 1984; 120: 502–4CrossRefGoogle Scholar
  65. 65.
    Obasi OE, Garg SK.: Bazex paraneoplastic acrokeratosis in prostate carcinoma. Br J Dermatol 1987; 117: 647–51PubMedCrossRefGoogle Scholar
  66. 66.
    Hara M, Hunayama M, Aiba S.: Acrokeratosis paraneoplastica (Bazex syndrome) associated with primary cutaneous squamous cell carcinoma of the lower leg, vitiligo and alopecia areata. Br J Dermatol 1995; 133: 121–4PubMedCrossRefGoogle Scholar
  67. 67.
    Martin RW, Cornitius TG, Naylor MF.: Bazex’s syndrome in a woman with pulmonary adenocarcinoma. Arch Dermatol 1989; 125: 847–8PubMedCrossRefGoogle Scholar
  68. 68.
    Clarke J.: Malignant acanthosis nigricans. Clin Exp Dermatol 1977; 2: 167–70PubMedCrossRefGoogle Scholar
  69. 69.
    Breathnach SM, Wells GC.: Acanthosis palmaris: tripe palms: a distinctive pattern of palmar keratoderma frequently associated with internal malignancy. Clin Exp Dermatol 1980; 5: 181–9PubMedCrossRefGoogle Scholar
  70. 70.
    Lo WL, Wong CK.: Tripe palms: a significant cutaneous sign of internal malignancy. Dermatology 1992; 185: 151–3PubMedCrossRefGoogle Scholar
  71. 71.
    Cohen PR, Kurzrock R.: Malignancy associated tripe palms. J Am Acad Dermatol 1992; 27 (2): 271–2PubMedCrossRefGoogle Scholar
  72. 72.
    Cohen PR, Grossman ME, Almeida L.: Tripe palms and malignancy. J Clin Oncol 1989; 7 (5): 669–78PubMedGoogle Scholar
  73. 73.
    Cohen PR, Grossman ME, Silvers DN.: Tripe palms and cancer. Clin Dermatol 1993; 11: 165–73PubMedCrossRefGoogle Scholar
  74. 74.
    Patel A, Teixeira F, Redington AE.: Palmoplantar keratoderma (tripe palms) associated with primary pulmonary adenocarcinoma. Thorax 2005; 60: 976PubMedCrossRefGoogle Scholar
  75. 75.
    Pentenero M, Carrozzo M, Pagano M.: Oral acanthosis nigricans, tripe palms and sign of Leser-Trélat in a patient with gastric adenocarcinoma. Int J Dermatol 2004; 43: 530–2PubMedCrossRefGoogle Scholar
  76. 76.
    Kebria MM, Belinson J, Kim R.: Malignant acanthosis nigricans, tripe palms and the sign of Leser-Trélat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol 2006; 101: 353–5PubMedCrossRefGoogle Scholar
  77. 77.
    McGinness J, Greer K.: Malignant acanthosis nigricans and tripe palms associated with pancreatic adenocarcinoma. Cutis 2006; 78 (1): 37–40PubMedGoogle Scholar
  78. 78.
    Berardesca E, Del Forno C, Vignini M.: Usefulness of etretinate treatment in paraneoplastic palmoplantar hyperkeratosis [letter]. Br J Dermatol 1987; 117(sn1): 132PubMedCrossRefGoogle Scholar
  79. 79.
    Marks R, Finlay AY, Holt PJA.: Severe disorders of keratinization: effects of treatment with Tigason (etretinate). Br J Dermatol 1981; 104: 667–73PubMedCrossRefGoogle Scholar
  80. 80.
    Kumar B, Kaur I, Thami GP.: Plantar psoriasis: clinical correlation of lesion pattern to weight bearing. Acta Derm Venereol 1995; 75: 157–8PubMedGoogle Scholar
  81. 81.
    Rai R, Saraswat A, Kaur I.: Marginal acrokeratoderma and psoriasis: is there an association? Int J Dermatol 2000; 39: 936–9PubMedCrossRefGoogle Scholar
  82. 82.
    Farber EM, Nall L.: Nonpustular palmoplantar psoriasis. Cutis 1992; 50: 407–10PubMedGoogle Scholar
  83. 83.
    Kumar B, Saraswat A, Inderjeet K.: Palmoplantar lesions in psoriasis: A study of 3065 patients. Acta Derm Venereol 2002; 82: 192–5PubMedCrossRefGoogle Scholar
  84. 84.
    Munro CS, Cox NH, Marks JM.: Lichen nitidus presenting as palmoplantar hyperkeratosis and nail dystrophy. Clin Exp Dermatol 1993; 18: 381–3PubMedCrossRefGoogle Scholar
  85. 85.
    Ashinoff R, Werth VP, Franks AG.: Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988; 19: 961–5PubMedCrossRefGoogle Scholar
  86. 86.
    English JC, McCollough ML.: Transient reactive papulotranslucent acrokeratoderma. J Am Acad Dermatol 1996; 34: 686–7PubMedCrossRefGoogle Scholar
  87. 87.
    Onwukwe MF, Mihm JrMC, Toda K.: Hereditary papulotranslucent acrokeratoderma: a new variant of familial punctate keratoderma? Arch Dermatol 1973; 108: 108–10PubMedCrossRefGoogle Scholar
  88. 88.
    Yan AC, Aasi SZ, Alms WJ.: Aquagenic palmoplantar keratoderma. J Am Acad Dermatol 2001; 44: 696–9PubMedCrossRefGoogle Scholar
  89. 89.
    Neri I, Bianchi F, Patrizi A. Transient aquagenic palmar hyperwrinkling: the first instance reported in a young boy. Pediatr Dermatol 2006; 23 (1): 39–42PubMedCrossRefGoogle Scholar
  90. 90.
    Baldwin BT, Prakash A, Fenske NA.: Aquagenic syringeal acrokeratoderma: report of a case with histologic findings. J Am Acad Dermatol 2006; 54 (5): 899–902PubMedCrossRefGoogle Scholar
  91. 91.
    Lowes MA, Khaira GS, Holt D.: Transient reactive papulotranslucent acrokeratoderma associated with cystic fibrosis. Aust J Dermatol 2000; 41: 172–4CrossRefGoogle Scholar
  92. 92.
    MacCormack MA, Wiss K, Malhotra R.: Aquagenic syringeal acrokeratoderma: report of two teenage cases. J Am Acad Dermatol 2001; 45: 124–6PubMedCrossRefGoogle Scholar
  93. 93.
    Itin PH, Lautenschlager S.: Aquagenic syringeal acrokeratoderma (transient reactive papulotranslucent acrokeratoderma). Dermatology 2002; 204: 8–11PubMedCrossRefGoogle Scholar
  94. 94.
    Betlloch I, Vergara G, Albares MP.: Aquagenic keratoderma. J Eur Acad Dermatol Venereol 2003; 17: 306–7PubMedCrossRefGoogle Scholar
  95. 95.
    Schmults C, Sidhu G, Urbanek W.: Aquagenic syringeal acrokeratoderma. Dermatol Online J 2003; 9: 27PubMedGoogle Scholar
  96. 96.
    Johns MK.: Skin wrinkling in cystic fibrosis. Med Biol Illustr 1975; 25: 205–10Google Scholar
  97. 97.
    Katz KA, Yan AC, Turner ML.: Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the delta F508 CFTR mutation. Arch Dermatol 2005; 141 (5): 621–4PubMedCrossRefGoogle Scholar
  98. 98.
    Carder KR, Weston WL.: Rofecoxib-induced instant aquagenic wrinkling of the palms. Pediatr Dermatol 2002; 19: 353–5PubMedCrossRefGoogle Scholar
  99. 99.
    Yalcin B, Artuz F, Toy GG.: Acquired aquagenic papulotranslucent acrokeratoderma. J Eur Acad Dermatol Venereol 2005; 19 (5): 654–6PubMedCrossRefGoogle Scholar
  100. 100.
    Heymann WR.: Hereditary papulotranslucent acrokeratoderma. Cutis 1998; 61: 29–30PubMedGoogle Scholar
  101. 101.
    Wilder-Smith EP, Chow A.: Water immersion wrinkling is due to vasoconstriction. Muscle Nerve 2003; 27: 307–11PubMedCrossRefGoogle Scholar
  102. 102.
    Mikhail GR, Babel D.: Trichophyton rubrum infection and keratoderma palmaris et plantaris. Arch Derm 1981; 117 (11): 753–4PubMedCrossRefGoogle Scholar
  103. 103.
    Premalatha S, Augustine SM, Yesudian P.: Punctate palmoplantar keratosis acuminate: an unusual form of tuberculid. Int J Dermatol 1982; 21: 470–1PubMedCrossRefGoogle Scholar
  104. 104.
    Mehlmauer MA.: Keratotic papules and nodules and hyperkeratosis of palms and soles in patients with tuberculosis and AIDS-related complex. J Am Acad Dermatol 1990; 23: 381–5PubMedCrossRefGoogle Scholar
  105. 105.
    Herman PS.: Punctate porokeratotic keratoderma. Dermatologica 1973; 147: 206–13PubMedCrossRefGoogle Scholar
  106. 106.
    Rault S, Salmon Ehr V, Cambie MP.: Palmoplantar filiform parakeratotic hyperkeratosis and digestive adenocarcinoma. Ann Dermatol Venereol 1997; 124 (10): 707–9PubMedGoogle Scholar
  107. 107.
    Wishart JM.: Bazex paraneoplastic acrokeratosis: a case report and response to Tigason. Br J Dermatol 1986; 115: 595–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Shaily Patel
    • 1
  • Matthew Zirwas
    • 2
  • Joseph C. EnglishIII
    • 1
  1. 1.Department of DermatologyUniversity of PittsburghPittsburghUSA
  2. 2.Division of DermatologyOhio State UniversityColumbusUSA

Personalised recommendations